[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341846-105":59,"doc-detail-341846-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","concomitant-or-antecedent-intraductal-papillary-mucinous-neoplasm-is-not-a-prognostic-factor-in-resected-pancreatic-cancer","Concomitant or antecedent intraductal papillary mucinous neoplasm is not a prognostic factor in resected pancreatic cancer","","Evaluated 187 patients who underwent resection for pancreatic adenocarcinoma or intraductal papillary mucinous neoplasm (IPMN)-related disease from January 2016 to December 2020, comparing overall survival across IPMN-associated pancreatic adenocarcinoma, conventional pancreatic adenocarcinoma, and IPMN. Overall survival was estimated with Kaplan–Meier methods and assessed with multivariate analysis. Resected IPMN showed long-term overall survival for most patients, while upfront resection yielded similar overall survival irrespective of IPMN status. No difference in median overall survival emerged between pancreatic adenocarcinoma and IPMN-associated adenocarcinoma, whereas tumor size, stage III, perineural invasion, lymphovascular invasion, positive nodes, and neoadjuvant treatment predicted worse outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/concomitant-or-antecedent-intraductal-papillary-mucinous-neoplasm-is-not-a-prognostic-factor-in-resected-pancreatic-cancer/341846/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/concomitant-or-antecedent-intraductal-papillary-mucinous-neoplasm-is-not-a-prognostic-factor-in-resected-pancreatic-cancer/341846.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the study regarding IPMN-associated pancreatic cancer?","Question",{"text":112,"@type":113},"To evaluate the prognosis of IPMN-associated pancreatic adenocarcinoma compared with conventional pancreatic adenocarcinoma in resected patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were overall survival outcomes analyzed?",{"text":117,"@type":113},"Overall survival was estimated using the Kaplan–Meier method, and associations between variables and disease-specific overall survival were assessed with multivariate analysis.",{"name":119,"@type":110,"acceptedAnswer":120},"Did the study find IPMN-associated adenocarcinoma to have a different prognosis than conventional pancreatic adenocarcinoma?",{"text":121,"@type":113},"No. Median overall survival did not differ significantly between resected pancreatic adenocarcinoma and IPMN-associated pancreatic adenocarcinoma, and the conclusion states they share the same prognosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341846,1790161933,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Concomitant or antecedent intraductal papillary mucinous  \nneoplasm is not a prognostic factor in resected pancreatic cancer  \nPedro Luiz Serrano Uson Junior1,2,3, Ana Luiza Spina Nagy1, Igor Wanderley Reis Dias1, Marcelo Bruno de Rezende1, Roberto Pestana1, Diogo Bugano1, Francisco Tustumi1, Guilherme Naccache Namur1, Jaime Arthur Pirola Kruger1, Alberto Goldenberg1,  \nSergio Eduardo Alonso Araujo1, Nam Jin Kim1, Sidney Klajner1, Mitesh Borad2, Fernando Moura1  \n1Center for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil; 2Mayo Clinic Cancer Center, Phoenix, AZ, USA; 3Department of Oncology, Hospital do Coração (HCOR), Sao Paulo, Brazil  \nContributions: (I) Conception and design: PLS Uson Junior, F Moura; (II) Administrative support: IWR Dias, SEA Araujo, NJ Kim, S Klajner, F Moura; (III) Provision of study materials or patients: MB de Rezende, R Pestana, D Bugano, F Tustumi, GN Namur, JAP Kruger, A Goldenberg, SEA Araujo, NJ Kim; (IV) Collection and assembly of data: PLS Uson Junior, F Moura, ALS Nagy; (V) Data analysis and interpretation: All authors;  \n(VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.  \nCorrespondence to: Pedro Luiz Serrano Uson Junior, MD. Center for Personalized Medicine, Hospital Israelita Albert Einstein, Av. Albert Einstein, São Paulo 627, Brazil; Mayo Clinic Cancer Center, 5881 E. Mayo Blvd., Phoenix, AZ 85054, USA; Department of Oncology, Hospital do Coração (HCOR), Rua Des. Eliseu Guilherme 147, Sao Paulo 04004-030, [Brazil. Email: pedro.serrano@einstein.br](Brazil. Email: pedro.serrano@einstein.br).  \nBackground: Intraductal papillary mucinous neoplasm (IPMN)-associated pancreatic cancer is becoming a common subtype of pancreatic cancer found in resected specimens. The prognostic of this subtype is still under evaluation. The study aims to evaluate the prognosis of IPMN-associated pancreatic adenocarcinoma  \ncompared to the conventional pancreatic adenocarcinoma.  \nMethods: In this study, patients with resected pancreatic neoplasms and IPMN treated at Hospital Israelita Albert Einstein, from January 2016 to December 2020, were analyzed. Overall survival (OS) was estimated using the Kaplan-Meier method, and correlations between the variables of interest and the disease specific  \nOS was assessed by multivariate analysis.  \nResults: Of 187 patients undergoing resection for pancreatic adenocarcinoma or IPMN, 125 (67%) had pancreatic adenocarcinoma, 33 (18%) had IPMN-associated pancreatic adenocarcinoma, and 29 (16%) had IPMN. Resected IPMN was associated with long-term OS for most of the patients. Similar OS was identified in this study in upfront resected pancreatic cancer associated or not with IPMN. No statistical differences in median OS were identified between resected pancreatic adenocarcinoma and IPMN-associated pancreatic adenocarcinoma (48 vs. 44 months, P=0.44) . Size of the tumor [hazard ratio (HR), 1.33], resected stage III (HR, 1.31), perineural invasion (HR, 1.58), lymphovascular invasion (HR, 1.44), positive lymph  \nnodes (HR, 1.34), and neoadjuvant treatment (HR, 1.70) were associated with worse outcomes.  \nConclusions: Our findings confirm that resected pancreatic cancer has a poor prognosis and IPMNassociated pancreatic adenocarcinoma has the same prognosis as a conventional pancreatic adenocarcinoma.  \nMore than half of the cases of IPMN-associated adenocarcinoma already had positive lymph nodes. The  \nimpact of neoadjuvant treatment in this group of patients should be investigated in larger cohorts.  \nKeywords: Intraductal papillary mucinous neoplasm (IPMN); pancreatic cancer; pancreatic neoplasms  \nSubmitted Mar 08, 2024. Accepted for publication Jun 07, 2024. Published online Jul 29, 2024.  \ndoi: 10.21037/jgo-24-157  \nView this article at: [https://dx.doi.org/10.21037/jgo-24-157](https://dx.doi.org/10.21037/jgo-24-157)  \n© Journal of Gastrointestinal Oncology. All rights reserved. J Gastrointest Oncol 2024;15(4):1","cbCaiq19Sc7S644w","https://ap.wps.com/l/cbCaiq19Sc7S644w","pdf",293043,"English","# Introduction\n# Highlight box\n## Key findings\n## What is known and what is new?\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What was the main objective of the study regarding IPMN-associated pancreatic cancer?\",\"answer\":\"To evaluate the prognosis of IPMN-associated pancreatic adenocarcinoma compared with conventional pancreatic adenocarcinoma in resected patients.\"},{\"question\":\"How were overall survival outcomes analyzed?\",\"answer\":\"Overall survival was estimated using the Kaplan–Meier method, and associations between variables and disease-specific overall survival were assessed with multivariate analysis.\"},{\"question\":\"Did the study find IPMN-associated adenocarcinoma to have a different prognosis than conventional pancreatic adenocarcinoma?\",\"answer\":\"No. Median overall survival did not differ significantly between resected pancreatic adenocarcinoma and IPMN-associated pancreatic adenocarcinoma, and the conclusion states they share the same prognosis.\"}]","Concomitant or antecedent intraductal papillary mucinous neoplasm is not a prognostic factor in resected pancreatic cancer | PDF",1790044161,18]